Skip to content

Cancer Genetics and Genomics Laboratory

BC Cancer

  • Home
  • Hematological
    • Acute Lymphoblastic Leukemia (Ph positive)
    • Acute Myeloid Leukemia (AML)
      • AML – ddPCR for inv16, t(8;21), or NPM1
      • AML – Rapid Mutation Panel
    • Acute Promyelocytic Leukemia (APL)
      • APL – FISH (Dx)
      • APL – RT-ddPCR (MRD)
      • APL – RTPCR
    • Chimerism
    • Chronic Lymphocytic Leukemia/Lymphoma (CLL)
    • Chronic Myeloid Leukemia (CML)
      • CML – FISH (Dx)
      • CML – QRTPCR
      • CML – RTPCR
      • CML – Kinase Domain
    • Lymphoma
      • Anaplastic Large Cell
      • Burkitt
      • Follicular
      • High-Grade B-Cell
      • IRF4 B-Cell Lymphoma
      • MALT
      • Mantle Cell
      • NHL – B/T-cell Clonality
    • Lymphoid and Myeloid Neoplasm with Eosinophilia
    • Multiple Myeloma
    • Myelodysplastic Syndrome (MDS)
    • Myeloproliferative Neoplasm (MPN)
    • VEXAS Syndrome
  • Solid Tumour
    • Colorectal Cancer
      • OncoPanel
      • BRAF V600
    • CNS
      • Focus Panel
      • Glioblastoma Multiforme (GBM)
      • Oligodendroglioma (ODG) 1p/19q FISH
    • Lung Cancer
      • ALK FISH
      • EGFR T790M (Plasma)
      • Focus Panel
    • Melanoma
      • OncoPanel
      • Focus Panel
      • BRAF V600
    • Mucoepidermoid Carcinoma
    • Sarcoma
      • Alveolar Rhabdomyosarcoma (ARMS)
      • Clear Cell Sarcoma
      • Dermatofibrosarcoma protuberens (DFSP)
      • Ewing Sarcoma
      • Liposarcoma
      • Low Grade Fibromyxoid Sarcoma
      • Myxoid Liposarcoma
      • Synovial Sarcoma
    • Prostate Cancer
    • Breast Cancer
    • DPYD Screening
  • Hereditary
    • Mainstreamed Hereditary Cancer Testing
  • Panels
    • CLL Panel
    • Focus Panel
    • Hereditary Cancer Panel
    • LExA
    • Myeloid Panel
    • OncoPanel
    • Optical Genome Mapping (OGM)
  • Guidelines
    • Specimens
    • Variants
    • FAQ
  • Studies
    • PREDICTm
    • [CLOSED]
  • Requisitions
  • Updates
  • Contact

KIT D816V/F – New test

2023/03/222019/03/29 by Curtis Hughesman

The Cancer Genetics and Genomics Laboratory’s (CGL) at BC Cancer has developed a new more sensitive test for detection of the KIT D816V and D816F mutations. Additional details on how the test has changed can be found in the below memo.

KIT D816VF MemoDownload
Categories Uncategorized
New FLT3 ITD and TKD test
© 2025 Cancer Genetics and Genomics Laboratory • Built with GeneratePress